HypnoVR
- Industry
- Digital Therapies
- Founded Year
- 2016
- Headquarters
- Strasbourg, France
- Employee Count
- 40
Key People
- Nicolas Schaettel - Co-founder, CEO
- Dr. Denis Graff - Co-founder, Product Expert
- Dr. Chlo Chauvin - Co-founder, Clinical Expert
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises experienced anesthetists and a seasoned entrepreneur, bringing a strong blend of medical and business expertise.
Dr. Denis Graff and Dr. Chlo Chauvin are anesthetists with extensive experience in medical hypnosis, while Nicolas Schaettel brings entrepreneurial acumen, creating a robust leadership team.
- Clinical Need
-
Aspect: Very Strong
Summary: HypnoVR addresses significant clinical needs in pain and anxiety management, offering non-pharmacological solutions.
Clinical studies have demonstrated HypnoVR's effectiveness in reducing post-operative pain and anxiety, highlighting its potential to improve patient outcomes and reduce reliance on medications.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for digital therapies is growing, with several players offering similar solutions.
The digital therapy market includes various companies developing VR-based solutions for pain and anxiety management, requiring HypnoVR to differentiate its offerings to maintain a competitive edge.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves integrating VR with medical hypnosis, which is complex but manageable.
Combining VR technology with medical hypnosis requires careful design and validation, but the processes are established, enabling HypnoVR to create effective and reliable solutions.
- Patent
-
Aspect: Strong
Summary: HypnoVR holds patents that protect its unique combination of VR and medical hypnosis.
By securing patents for its innovative approach, HypnoVR can safeguard its technology and maintain a unique position in the digital therapy landscape.
- Financing
-
Aspect: Well-funded
Summary: HypnoVR has secured significant funding to support its growth and development.
With a 4.5 million Series A funding round led by prominent investors, HypnoVR is well-positioned to accelerate its commercial roll-out and invest in further R&D.
- Regulatory
-
Aspect: 510k/PMA
Summary: HypnoVR's solutions are CE marked as Class I medical devices, indicating compliance with European regulatory standards.
Achieving CE marking demonstrates that HypnoVR's products meet essential health and safety requirements, enabling their use across European healthcare institutions.
Opportunity Rollup
- Odds of Success
- 3.5
- Peak Market Share
- 4.4
- Segment CAGR
- 10.7%
- Market Segment
- Digital Therapies
- Market Sub Segment
- Pain and Anxiety Management
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
HypnoVR's innovative combination of VR and medical hypnosis addresses a significant clinical need, positioning the company for growth in the expanding digital therapy market.